TICKERNERD
Menu
EYPTEYPTHealthcare · Biotechnology

EYPT Stock Forecast: EyePoint, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$15
+9.42% on the day

The 14 Wall Street analysts covering EyePoint, Inc. hold a median 12-month price target of $38 — +157.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 15 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.2B
Ticker Nerd rank
22 / 100
Median analyst target
$38
Analysts covering
14
Total return, dividends reinvested
1W
+6.2%
1M
+7.4%
YTD
−19.3%
1Y
+35.9%
From 52W high
−21.8%
From 52W low
+35.9%
$11
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EYPT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores EyePoint, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
22 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
78
Momentum
58
Size
43
Value
43
Revisions
34
Volatility
28
Issuance
25
Growth
23
Quality
20

Accruals (78): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (20): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EYPT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EYPT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26EYPTHigh $68Median $38Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $20Median $38High $68

The green dot is the last close — the median target sits +157.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
7 Aug 2026Chardan CapitalMaintainsBuy$65
6 Aug 2026Cantor FitzgeraldMaintainsOverweight$47 → $55
6 Aug 2026HC Wainwright & Co.MaintainsBuy$30 → $27
16 July 2026StifelInitiatesBuy$40
16 July 2026StifelInitiatesBuy—
8 July 2026Cantor FitzgeraldAssumesOverweight$47
1 July 2026Chardan CapitalMaintainsBuy$29 → $65
1 July 2026Chardan CapitalMaintainsBuy—
24 June 2026GuggenheimReiteratesBuy—
7 May 2026RBC CapitalMaintainsOutperform—
9 Mar 2026CitigroupMaintainsBuy—
5 Mar 2026HC Wainwright & Co.MaintainsBuy—
4 Mar 2026Chardan CapitalMaintainsBuy—
6 Nov 2025RBC CapitalMaintainsOutperform—
7 Aug 2025Chardan CapitalMaintainsBuy—
6 Aug 2025HC Wainwright & Co.MaintainsBuy—
17 June 2025RBC CapitalInitiatesOutperform—
29 May 2025HC Wainwright & Co.ReiteratesBuy—
16 May 2025MizuhoMaintainsOutperform—
8 May 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EYPT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

EYPT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

EyePoint, Inc. (EYPT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.7×

Cheaper than 89% of US stocks

Price / sales
443.6×

Cheaper than 2% of US stocks

Price / book
37.2×

Cheaper than 3% of US stocks

EV / EBITDA
−4.4×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
161.7%

Higher than 95% of US stocks

Earnings growth (YoY)
−90.5%

Higher than 3% of US stocks

Gross margin
100.0%

Higher than 99% of US stocks

Operating margin
−450.7%

Higher than 8% of US stocks

Net margin
93.4%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−148.7%

Higher than 9% of US stocks

Return on assets
−74.9%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

EYPT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EYPTEyePoint, Inc.$1.2B
22
OMEROmeros Corp.$1.2B
90
LTGOLatigo Biotherapeutics, Inc.$1.2B
0
REPLReplimune Group, Inc.$1.2B
34
CRVSCorvus Pharmaceuticals, Inc.$1.2B
55
ANROAlto Neuroscience, Inc.$1.2B
55
CGEMCullinan Therapeutics, Inc.$1.3B
71

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own EyePoint, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EYPT news & analysis

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewsWire · 14 Aug 2026neutral

EyePoint, Inc. announced that it granted non-statutory stock options to new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4), outside its 2023 Long-Term Incentive Plan. The grants were made to support hiring as part of the company's work developing treatments for serious retinal diseases.

Why it matters — EYPT watchers would care because this indicates the company is hiring new staff, potentially expanding its operations, and the inducement grants reflect equity-based compensation practices that can affect share dilution.

EyePoint: Phase 3 Design Creates A More Valuable Durability Story

Seeking Alpha · 8 Aug 2026positive

EyePoint Pharmaceuticals is approaching pivotal Phase III LUGANO data for DURAVYU in wet AMD, expected around August 2026. The program emphasizes repeat six-month dosing, broad patient inclusion, and a head-to-head comparison with on-label aflibercept, while the company's manufacturing ownership and Durasert E platform extend to both wet AMD and DME.

Why it matters — An EYPT watcher would care because the LUGANO readout represents a pivotal inflection point for DURAVYU's durability story and the company's strategic value.

EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 5 Aug 2026negative

EyePoint reported a second-quarter loss of $1.09 per share, versus the Zacks Consensus Estimate of a $0.92 loss and a $0.85 loss per share in the same quarter a year ago. According to the headline, revenue beat estimates.

Why it matters — EYPT watchers would note that the company's quarterly loss came in wider than analysts expected and widened from the prior-year period, even as revenue reportedly topped expectations.

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

GlobeNewsWire · 5 Aug 2026positive

EyePoint reported Q2 2026 financial results and provided updates on its clinical pipeline, including expected topline data from the LUGANO and LUCIA Phase 3 wet AMD trials in August and Q4 2026, respectively, and from the COMO and CAPRI DME trials in Q4 2027. The company ended the quarter with $180 million in cash, projecting runway into Q4 2027.

Why it matters — EYPT watchers will be watching for multiple pivotal trial readouts starting in August 2026, with the company's cash position extending through key milestones.

FAQ

Frequently asked questions about EYPT stock

What is the EYPT stock price forecast for 2026-2027?

The 14 Wall Street analysts covering EyePoint, Inc. have a median 12-month price target of $38, with estimates ranging from $20 to $68. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EYPT stock a buy right now?

Of the 14 analysts covering EyePoint, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks EyePoint, Inc. 22 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EYPT?

As at 15 Aug 2026, EyePoint, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (78 of 100).

Will EYPT stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +157.6% from the last close, and Ticker Nerd's factor model ranks EyePoint, Inc. 22 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EYPT stock forecast for 2030?

No analyst covering EyePoint, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EYPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $68 over the next 12 months.

How has EYPT stock performed over the past year?

EyePoint, Inc. returned +35.9% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does EyePoint, Inc. do?

EyePoint Pharmaceuticals Inc. is a specialty biopharmaceutical company focused on developing and commercializing innovative ophthalmic products.

What is the latest news on EYPT?

The most recent item we track (GlobeNewsWire, 14 Aug 2026): "EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)". EyePoint, Inc. announced that it granted non-statutory stock options to new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4), outside its 2023 Long-Term Incentive Plan. The grants were made to support hiring as part of the company's work developing treatments for serious retinal diseases.

Company

About EyePoint, Inc.

EyePoint Pharmaceuticals Inc. is a specialty biopharmaceutical company focused on developing and commercializing innovative ophthalmic products. Its primary purpose is to treat serious eye disorders, particularly targeting diseases like wet age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion. EyePoint's unique approach leverages drug delivery technologies which offer sustained-release treatments, enhancing patient outcomes by providing consistent therapeutic levels over extended periods. The company operates within the biotechnology and healthcare sectors, impacting the pharmaceutical landscape by addressing unmet medical needs in ophthalmology. EyePoint Pharmaceuticals plays a significant role in the market through collaborations with leading eye care companies, advancing therapeutic research and expanding access to novel solutions for visual impairment. Based in Watertown, Massachusetts, the company continues to innovate and lead in the field of ocular drug development, contributing to the advancement of vision-related healthcare on a global scale.

CEO Dr. Jay S. Duker M.D. · 214 employees · United States · https://eyepoint.bio